Luke Dickinson has joined health and science communications firm Spectrum as its new account director.
Dickinson’s career spans a wide range of industries, including renewable and non-renewable energy, pharmacy and medical devices.
A spokesperson for the company said: “He brings significant experience in the areas of FDA-product approval, consumer-confidence boosting and brand building for energy and pharmaceutical corporations.”
Amgen has selected Robert Bradway as a new board member.
He joined Amgen in 2006 as vice president of operations strategy, and became executive vice president and chief financial officer in 2007, before moving up the ranks to become president and chief operating officer – the positions he currently holds.
The addition of Bradway brings the board’s headcount up to 13.
Subramanyam Maddala has become president of Indian operations at AMRI.
In his new role, Maddala will take charge of the firm’s Indian API manufacturing, including operations at its facilities in Hyderabad and Aurangabad.
He comes to AMRI from Shasun Pharmaceuticals, where he served as vice president of contract research and manufacturing services new generics.
Dr. Steven Hagen, vice president of pharmaceutical development and manufacturing at AMRI said: “We are pleased to welcome Mr. Maddala to the AMRI leadership team and believe he is the right person to take AMRI’s chemical manufacturing business in India to the next level, including the capability to eventually manufacture multiple products in India to U.S. FDA standards.”
vivoPharm has appointed Ian Nisbet as chairman of the board.
A founder and partner in the biotechnology consulting company Afandin, Nisbet is also currently chairman of Verva Pharmaceuticals, and non-executive director of Velacor.
The announcement comes as the Australian firm sets its sights on the US market.
“vivoPharm has established a successful service business in Australia and is poised to establish its presence in the US.
“It is an honour to join the Board at this time and I look forward to using my knowledge and networks in the oncology sector to help build vivoPharm into the premier global oncology-focused preclinical contract research organisation," said Nisbet.
Novel obesity therapeutics company Zafgen has drafted Frances Heller onto its board of directors.
The company say her appointment will be “invaluable” to the progress of its lead molecule, beloranib, into Phase 2 clinical trials.
Prior to Zafgen, Heller was executive vice president of business development at Exelixis Pharmaceuticals.
“Zafgen is a unique pharmaceutical company with a truly innovative approach to tackling obesity at its root cause,” said Heller. “I am honored to join the exceptional team at Zafgen as the company reaches its goal of bringing its promising lead molecule, beloranib, to the market for severely obese patients.”
Frontage Laboratories has named Li Liu as executive director of biometrics for their clinical services team.
Prior to joining Frontage, Liu spent seven years at Research Pharmaceutical Services, where he held several managerial positions ranging from senior biostatistician to director of biostatistics and programming.
A spokesperson for the firm said: “With the addition of Dr. Liu, Frontage now provides a broader and higher quality range of services to our clients to meet their biostatistics needs.”